Press-release for stocks publishing date 2022 - 08

Prices are updated after-hours

publishing date : 2022 - 08 - 09 tags : Therapeutics

save search

eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-08-09 (Crawled : 23:00) - biospace.com/
EFTR | $1.85 -4.64% -6.59% 110K

| 106.13% | O: 4.55% H: 112.09% C: -30.51%
therapeutics update results

Bone Therapeutics to broaden and derisk therapeutic portfolio by acquiring majority participation in Medsenic
Published: 2022-08-09 (Crawled : 23:00) - globenewswire.com
ARVL | News | $0.49 0.37% 2.5M

Manufacturing

| -69.27% | O: 0.0% H: 0.0% C: 0.0%
bone therapeutics

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Published: 2022-08-09 (Crawled : 22:00) - globenewswire.com
CDTX | News | $12.29 19.9% 14.15% 57K

Health Technology

| 1683.71% | O: 0.8% H: 11.09% C: 4.75%
therapeutics update results

Summit Therapeutics Closes Fully-Subscribed $100 Million Rights Offering
Published: 2022-08-09 (Crawled : 18:00) - globenewswire.com
SMMT | $3.605 -3.35% -3.47% 1.3M

Health Technology

| 259.0% | O: 0.0% H: 2.0% C: -3.4%
offering therapeutics

ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
Published: 2022-08-09 (Crawled : 17:00) - biospace.com/
ADCT | $4.78 -3.82% 1.88% 280K

Health Technology

| -40.62% | O: -2.24% H: 2.67% C: 1.27%
therapeutics results

Vivos Therapeutics Schedules Second Quarter 2022 Financial Results Conference CallCall Scheduled for Monday, August 15, 2022 at 5:00 pm ET
Published: 2022-08-09 (Crawled : 16:00) - biospace.com/
VVOS | $2.58 -2.64% -2.71% 75K

Health Technology

| 97.69% | O: -2.31% H: 1.57% C: -4.72%
conference therapeutics

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
Published: 2022-08-09 (Crawled : 15:20) - biospace.com/
PRLD | $3.87 1.02% 29K

Health Technology

| -40.92% | O: -1.53% H: 1.86% C: 0.93%
therapeutics update results

MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results
Published: 2022-08-09 (Crawled : 15:20) - biospace.com/
INKT | $0.889 2.07% 0.11% 39K

| -34.56% | O: -2.21% H: 7.52% C: -0.75%
therapeutics update results

Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
Published: 2022-08-09 (Crawled : 14:20) - biospace.com/
OVID | $3.15 -1.56% -1.11% 110K

Health Technology

| 43.18% | O: -1.36% H: 2.3% C: 0.46%
therapeutics results

Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates
Published: 2022-08-09 (Crawled : 14:00) - biospace.com/
VIRX | $0.8367 -1.31% -1.33% 55K

Manufacturing

| -78.73% | O: -3.04% H: 0.0% C: -9.4%
therapeutics results

Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer
Published: 2022-08-09 (Crawled : 14:00) - biospace.com/
KTRA | $0.1373 3.47% 3.42% 5.8M

Distribution Services

| -98.6% | O: 10.0% H: 1.82% C: -17.73%
rem-001 fda therapeutics cancer study metastatic breast cancer

Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells from TCR-CAR+ Induced Pluripotent Stem Cells
Published: 2022-08-09 (Crawled : 14:00) - biospace.com/
FATE | News | $4.3 -5.29% -5.58% 1.7M

Health Technology

| -87.4% | O: -3.49% H: 1.73% C: -0.33%
preclinical therapeutics publication

VistaGen Therapeutics to Report Fiscal Year 2023 First Quarter Financial Results on August 11, 2022
Published: 2022-08-09 (Crawled : 13:20) - biospace.com/
VTGN | $4.75 -1.66% -1.68% 150K

Health Technology

| -5.51% | O: -0.9% H: 0.0% C: -4.36%
report year therapeutics results

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
Published: 2022-08-09 (Crawled : 13:20) - biospace.com/
RLMD | $3.86 -1.28% -1.56% 110K

Health Technology

| -85.96% | O: 1.56% H: 0.11% C: -2.43%
rel-1017 treatment fda designation therapeutics fast track designation major depressive disorder

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates
Published: 2022-08-09 (Crawled : 13:00) - biospace.com/
HRTX M | $2.65 -5.36% -5.26% 2.2M

Health Technology

| -25.77% | O: -6.16% H: 30.75% C: 22.69%
six therapeutics

Trevi Therapeutics to Present at Upcoming August Conferences
Published: 2022-08-09 (Crawled : 12:20) - biospace.com/
TRVI | $2.68 -5.97% -6.34% 120K

Health Technology

| -38.08% | O: 8.41% H: 0.94% C: -11.85%
therapeutics

Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results
Published: 2022-08-09 (Crawled : 12:20) - biospace.com/
XLO | $1.06 0.95% 0.94% 300K

Professional, Scientific, and T...

| -67.68% | O: -25.61% H: 20.9% C: -0.82%
xtx101 therapeutics

Heron Therapeutics Announces $76.5 Million Private Placement Financing
Published: 2022-08-09 (Crawled : 12:20) - prnewswire.com
HRTX M | $2.65 -5.36% -5.26% 2.2M

Health Technology

| -25.77% | O: -6.16% H: 30.75% C: 22.69%
therapeutics